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AML is most common type of leukemia in adults
1 in 4 adults survive longer
than 5 year









Acute Myeloid Leukemia (AML) 
AIM: Explore the metabolic inhibition as a therapeutic approach in AML in combination with classical chemotherapy regimens
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Pre-treatment (PT)
PTCTR
16 hours glycolytic inhibitor: 
3-Bromopyruvate (3-BP)
Treatment 
















































IC50 = 0.008 ±0.005 µM
IC50 = 0.021 ±0.009 µM IC50 = 0.368 ±0.175 µM
IC50 = 0.139 ±0.064 µM
IC50 = 3.627 ±2.131 µM
IC50 = 1.767 ±1.698 µM
IC50 = 0.017 ±0.008 µM
IC50 = 0.020 ±0.009 µM












5µM 3-BP sensitize AML cells to DNR and/or Ara-C3.1
Figure 1. Effect of 3-BP pre-treatment on daunorubicin and cytarabine cytotoxicity in KG-1 and
MOLM13 cells by trypan blue assay.
5µM 3-BP do not induce cell death or loss in viability of AML cells3.2
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Figure 2. Characterization of apoptotic effect of 5 µM of 3-BP in AML cell lines by flow cytometry.
Cell line KG-1 MOLM13
3-BP (µM) 0 5 20 0 5 20
Cell viability (%) 100.00 109.86 38.96 100.00 146.26 70.70
± SD 4.94 8.43 22.06 7.20 23.93 14.38
Table 1. Effect of 5 µM 3-BP on AML cell viability. MOLM13 and KG-1 cell viability
was evaluated by MTS assay.







Pre-treated with 5 µM 3-BP










































110 - 0 7
210 - 0 7
310 - 0 7
MOLM 13










Figure 3. Characterization of 3-BP effect on AML glycolytic profile using commercial enzymatic colorimetric kits.








5µM 3-BP decrease glucose consumption in AML cells3.3
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5µM 3-BP do not affect AML extracellular lactate levels, 
suggesting that non-toxic concentration of 3-BP may 
affect other metabolic pathway(s)
Untreated
































































































Figure 4. Characterization of mitochondrial activity and ROS levels of AML
cells in the presence of 3-BP for 16 h. *p < 0.05; ns: no statistically significant.
Figure 5. Characterization of 5µM of 3-BP effect on glutathione levels of 
MOLM13 and KG-1 cell lines. **p < 0.01.
5µM 3-BP decrease the redox potential of AML 
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Pre-treatment with a non-toxic concentration of 3-BP boosts effect of chemotherapy in AML cell 
lines as result of combined mechanisms
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